Luigi Taranto-Montemurro1, Ludovico Messineo2, Ali Azarbarzin3, Daniel Vena3, Lauren B Hess3, Nicole A Calianese3, David P White3, Andrew Wellman3, Scott A Sands3. 1. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA. Electronic address: ltarantomontemurro@bwh.harvard.edu. 2. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA; Respiratory Medicine and Sleep Laboratory, Department of Internal Medicine, Spedali Civili di Brescia, University of Brescia, Brescia, Italy; Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia. 3. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: We recently showed that administration of the combination of the noradrenergic drug atomoxetine plus the antimuscarinic oxybutynin (ato-oxy) prior to sleep greatly reduced OSA severity, likely by increasing upper airway dilator muscle activity during sleep. In patients with OSA who performed the ato-oxy trial with an esophageal pressure catheter to estimate ventilatory drive, the effect of the drug combination (n = 17) and of the single drugs (n = 6) was measured on the endotypic traits over a 1-night administration and compared vs placebo. This study also tested if specific traits were predictors of complete response to treatment (reduction in apnea-hypopnea index [AHI] > 50% and < 10 events/h). METHODS: The study was a double-blind, randomized, placebo-controlled trial. The arousal threshold, collapsibility (ventilation at eupneic drive [Vpassive]), ventilation at arousal threshold, and loop gain (stability of ventilatory control, LG1), were calculated during spontaneous breathing during sleep. Muscle compensation (upper airway response) was calculated as a function of ventilation at arousal threshold adjusted for Vpassive. Ventilation was expressed as a percentage of the eupneic level of ventilation (%eupnea). Data are presented as mean [95% CI]. RESULTS: Compared with placebo, ato-oxy increased Vpassive by 73 [54 to 91]%eupnea (P < .001) and muscle compensation by 29 [8 to 51]%eupnea (P = .012), reduced the arousal threshold by -9 [-14 to -3]% (P = .022) and LG1 by -11 [-22 to 2]% (P = .022). Atomoxetine alone significantly reduced arousal threshold and LG1. Both agents alone improved collapsibility (Vpassive) but not muscle compensation. Patients with lower AHI, higher Vpassive, and higher fraction of hypopneas over total events had a complete response with ato-oxy. FINDINGS: Ato-oxy markedly improved the measures of upper airway collapsibility, increased breathing stability, and slightly reduced the arousal threshold. Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.
RCT Entities:
BACKGROUND: We recently showed that administration of the combination of the noradrenergic drug atomoxetine plus the antimuscarinic oxybutynin (ato-oxy) prior to sleep greatly reduced OSA severity, likely by increasing upper airway dilator muscle activity during sleep. In patients with OSA who performed the ato-oxy trial with an esophageal pressure catheter to estimate ventilatory drive, the effect of the drug combination (n = 17) and of the single drugs (n = 6) was measured on the endotypic traits over a 1-night administration and compared vs placebo. This study also tested if specific traits were predictors of complete response to treatment (reduction in apnea-hypopnea index [AHI] > 50% and < 10 events/h). METHODS: The study was a double-blind, randomized, placebo-controlled trial. The arousal threshold, collapsibility (ventilation at eupneic drive [Vpassive]), ventilation at arousal threshold, and loop gain (stability of ventilatory control, LG1), were calculated during spontaneous breathing during sleep. Muscle compensation (upper airway response) was calculated as a function of ventilation at arousal threshold adjusted for Vpassive. Ventilation was expressed as a percentage of the eupneic level of ventilation (%eupnea). Data are presented as mean [95% CI]. RESULTS: Compared with placebo, ato-oxy increased Vpassive by 73 [54 to 91]%eupnea (P < .001) and muscle compensation by 29 [8 to 51]%eupnea (P = .012), reduced the arousal threshold by -9 [-14 to -3]% (P = .022) and LG1 by -11 [-22 to 2]% (P = .022). Atomoxetine alone significantly reduced arousal threshold and LG1. Both agents alone improved collapsibility (Vpassive) but not muscle compensation. Patients with lower AHI, higher Vpassive, and higher fraction of hypopneas over total events had a complete response with ato-oxy. FINDINGS:Ato-oxy markedly improved the measures of upper airway collapsibility, increased breathing stability, and slightly reduced the arousal threshold. Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.
Authors: Bradley A Edwards; Scott A Sands; Robert L Owens; Danny J Eckert; Shane Landry; David P White; Atul Malhotra; Andrew Wellman Journal: Sleep Date: 2016-11-01 Impact factor: 5.849
Authors: Luigi Taranto-Montemurro; Bradley A Edwards; Scott A Sands; Melania Marques; Danny J Eckert; David P White; Andrew Wellman Journal: Am J Respir Crit Care Med Date: 2016-10-01 Impact factor: 21.405
Authors: Philip I Terrill; Bradley A Edwards; Shamim Nemati; James P Butler; Robert L Owens; Danny J Eckert; David P White; Atul Malhotra; Andrew Wellman; Scott A Sands Journal: Eur Respir J Date: 2014-10-16 Impact factor: 16.671
Authors: Richard B Berry; Rohit Budhiraja; Daniel J Gottlieb; David Gozal; Conrad Iber; Vishesh K Kapur; Carole L Marcus; Reena Mehra; Sairam Parthasarathy; Stuart F Quan; Susan Redline; Kingman P Strohl; Sally L Davidson Ward; Michelle M Tangredi Journal: J Clin Sleep Med Date: 2012-10-15 Impact factor: 4.062
Authors: Andrew Wellman; Bradley A Edwards; Scott A Sands; Robert L Owens; Shamim Nemati; James Butler; Chris L Passaglia; Andrew C Jackson; Atul Malhotra; David P White Journal: J Appl Physiol (1985) Date: 2013-01-24
Authors: Aurélie P Weerts; Nathalie Pattyn; Lakshmi Putcha; Stephen W Hoag; Angelique Van Ombergen; Emma Hallgren; Paul H Van de Heyning; Floris L Wuyts Journal: J Psychopharmacol Date: 2015-08-12 Impact factor: 4.153
Authors: Scott A Sands; Bradley A Edwards; Philip I Terrill; Luigi Taranto-Montemurro; Ali Azarbarzin; Melania Marques; Lauren B Hess; David P White; Andrew Wellman Journal: Am J Respir Crit Care Med Date: 2018-05-01 Impact factor: 30.528
Authors: Raichel M Alex; Tamar Sofer; Ali Azarbarzin; Daniel Vena; Laura K Gell; Andrew Wellman; David P White; Susan Redline; Scott A Sands Journal: Sleep Date: 2022-09-08 Impact factor: 6.313
Authors: Christopher N Schmickl; Jeremy E Orr; Paul Kim; Brandon Nokes; Scott Sands; Sreeganesh Manoharan; Lana McGinnis; Gabriela Parra; Pamela DeYoung; Robert L Owens; Atul Malhotra Journal: BMC Pulm Med Date: 2022-04-25 Impact factor: 3.320
Authors: Daniel Vena; Luigi Taranto-Montemurro; Ali Azarbarzin; Sara Op de Beeck; Melania Marques; Olivier M Vanderveken; Bradley A Edwards; Laura Gell; Nicole Calianese; Lauren B Hess; Reza Radmand; Garun S Hamilton; Simon A Joosten; Johan Verbraecken; Marc Braem; David P White; Susan Redline; Scott A Sands; Andrew Wellman Journal: Sleep Date: 2022-06-13 Impact factor: 6.313
Authors: Atqiya Aishah; Richard Lim; Scott A Sands; Luigi Taranto-Montemurro; Andrew Wellman; Jayne C Carberry; Danny J Eckert Journal: J Appl Physiol (1985) Date: 2021-03-18
Authors: Brendan M Doyle; Michele L Singer; Thomaz Fleury-Curado; Sabhya Rana; Ethan S Benevides; Barry J Byrne; Vsevolod Y Polotsky; David D Fuller Journal: Gene Ther Date: 2021-02-11 Impact factor: 5.250
Authors: Paula K Schweitzer; James P Maynard; Paul E Wylie; Helene A Emsellem; Scott A Sands Journal: Sleep Breath Date: 2022-05-13 Impact factor: 2.655
Authors: Elahe Kazemeini; Eli Van de Perck; Marijke Dieltjens; Marc Willemen; Johan Verbraecken; Sara Op de Beeck; Olivier M Vanderveken Journal: Front Neurol Date: 2022-02-22 Impact factor: 4.003